First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN

被引：0
|
作者：
Hou, X. [1 ]
Zhou, C. [2 ]
Wu, G. [3 ]
Lin, W. [4 ]
Xie, Z.
Zhang, H. [2 ,5 ,6 ]
Yi, J. [7 ]
Peng, Z. [8 ]
Yin, L. [8 ]
Ma, C. [8 ]
Chen, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Meizhou Peoples Hosp, Huangtang Hosp, Meizhou, Peoples R China
[4] Shantou Univ, Canc Hosp, Med Coll, Shantou, Peoples R China
[5] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China
[6] Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Guangzhou, Peoples R China
[7] Guangzhou Red Cross Hosp, Guangzhou, Peoples R China
[8] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-squamous non-small-cell lung cancer; Brain metastases; Immunochemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-04
引用
收藏
页码：S318 / S318
页数：1
相关论文
共 50 条
  • [31] First-Line Atezolizumab Chemoimmunotherapy in Advanced Non-Squamous NSCLC Patients Harboring EGFR/ALK Genetic Alterations
    Thein, K.
    Jahan, N.
    Tun, A.
    Sultan, A.
    Swarup, S.
    Mogollon-Duffo, F.
    Yendala, R.
    Quirch, M.
    Htut, T.
    D'Cunha, N.
    Rehman, S.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S259 - S259
  • [32] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [33] Pemetrexed-Carboplatin Versus Paclitaxel (Weekly)-Carboplatin as First Line Chemotherapy in Advanced Non-Squamous NSCLC
    Malik, P.
    Yadav, A.
    Jain, D.
    Pathy, S.
    Mohan, A.
    Khurana, S.
    Kumar, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S354 - S355
  • [34] MO19390 (SAiL): hypertension in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy
    Thatcher, Nicholas
    Tsai, Chun-Ming
    Laskin, Janessa
    Crino, Lucio
    Pavlakis, Nick
    Garrido, Pilar
    Dansin, Eric
    Bearz, Alessandra
    Hirsh, Veral
    Griesinger, Frank
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S358 - S359
  • [35] Cost-effectiveness analysis of sintilimab plus chemotherapy versus camrelizumab plus chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
    Rui, Mingjun
    Fei, Zhengyang
    Wang, Yingcheng
    Zhang, Xueke
    Ma, Aixia
    Sun, Haikui
    Li, Hongchao
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 618 - 629
  • [36] MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC
    Dansin, Eric
    Cinieri, Saverio
    Garrido, Pilar
    Griesinger, Frank
    Isla, Dolores
    Koehler, Manfred
    Kohlhaeufl, Martin
    LUNG CANCER, 2012, 76 (03) : 373 - 379
  • [37] Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
    Gong, Jinhong
    Shang, Jingjing
    Su, Dan
    Qian, Xiaodan
    Liu, Guangjun
    Sun, Zhiqiang
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 709 - 717
  • [38] Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
    Wang, Jing
    Chen, Qin
    Wang, Xinyue
    Huang, Dingzhi
    Jiang, Richeng
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (05)
  • [39] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial
    Qin, B.
    Zhai, J.
    Lu, D.
    Ge, X.
    Mao, Y.
    Sheng, S.
    Hu, Y.
    Wang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S322
12345